Anthony Arguelles Arias1, Marc Ongena2, Bart Devreese3, Mohammed Terrak1, Bernard Joris1, Patrick Fickers4. 1. Centre d'Ingénierie des Protéines, Bacterial Physiology and Genetics, Université de Liège, Liège, Belgium. 2. Centre Wallon de Biologie Industrielle, Unité de Bioindustrie, Faculté de Sciences Agronomique de Gembloux, Gembloux, Belgium . 3. Laboratorium voor Eiwitbiochemie en Eiwitengineering, Universiteit-Gent, Gent, Belgium. 4. Unité de Biotechnologies et Bioprocédés, Université Libre de Bruxelles, Brussels, Belgium.
Abstract
BACKGROUND: Lantibiotics are heat-stable peptides characterized by the presence of thioether amino acid lanthionine and methyllanthionine. They are capable to inhibit the growth of Gram-positive bacteria, including Listeria monocytogenes, Staphylococcus aureus or Bacillus cereus, the causative agents of food-borne diseases or nosocomial infections. Lantibiotic biosynthetic machinery is encoded by gene cluster composed by a structural gene that codes for a pre-lantibiotic peptide and other genes involved in pre-lantibiotic modifications, regulation, export and immunity. METHODOLOGY/ FINDINGS: Bacillus amyloliquefaciens GA1 was found to produce an antimicrobial peptide, named amylolysin, active on an array of Gram-positive bacteria, including methicillin resistant S. aureus. Genome characterization led to the identification of a putative lantibiotic gene cluster that comprises a structural gene (amlA) and genes involved in modification (amlM), transport (amlT), regulation (amlKR) and immunity (amlFE). Disruption of amlA led to loss of biological activity, confirming thus that the identified gene cluster is related to amylolysin synthesis. MALDI-TOF and LC-MS analysis on purified amylolysin demonstrated that this latter corresponds to a novel lantibiotic not described to date. The ability of amylolysin to interact in vitro with the lipid II, the carrier of peptidoglycan monomers across the cytoplasmic membrane and the presence of a unique modification gene suggest that the identified peptide belongs to the group B lantibiotic. Amylolysin immunity seems to be driven by only two AmlF and AmlE proteins, which is uncommon within the Bacillus genus. CONCLUSION/SIGNIFICANCE: Apart from mersacidin produced by Bacillus amyloliquefaciens strains Y2 and HIL Y-85,544728, reports on the synthesis of type B-lantibiotic in this species are scarce. This study reports on a genetic and structural characterization of another representative of the type B lantibiotic in B. amyloliquefaciens.
BACKGROUND: Lantibiotics are heat-stable peptides characterized by the presence of thioether amino acid lanthionine and methyllanthionine. They are capable to inhibit the growth of Gram-positive bacteria, including Listeria monocytogenes, Staphylococcus aureus or Bacillus cereus, the causative agents of food-borne diseases or nosocomial infections. Lantibiotic biosynthetic machinery is encoded by gene cluster composed by a structural gene that codes for a pre-lantibiotic peptide and other genes involved in pre-lantibiotic modifications, regulation, export and immunity. METHODOLOGY/ FINDINGS:Bacillus amyloliquefaciensGA1 was found to produce an antimicrobial peptide, named amylolysin, active on an array of Gram-positive bacteria, including methicillin resistant S. aureus. Genome characterization led to the identification of a putative lantibiotic gene cluster that comprises a structural gene (amlA) and genes involved in modification (amlM), transport (amlT), regulation (amlKR) and immunity (amlFE). Disruption of amlA led to loss of biological activity, confirming thus that the identified gene cluster is related to amylolysin synthesis. MALDI-TOF and LC-MS analysis on purified amylolysin demonstrated that this latter corresponds to a novel lantibiotic not described to date. The ability of amylolysin to interact in vitro with the lipid II, the carrier of peptidoglycan monomers across the cytoplasmic membrane and the presence of a unique modification gene suggest that the identified peptide belongs to the group B lantibiotic. Amylolysin immunity seems to be driven by only two AmlF and AmlE proteins, which is uncommon within the Bacillus genus. CONCLUSION/SIGNIFICANCE: Apart from mersacidin produced by Bacillus amyloliquefaciens strains Y2 and HIL Y-85,544728, reports on the synthesis of type B-lantibiotic in this species are scarce. This study reports on a genetic and structural characterization of another representative of the type B lantibiotic in B. amyloliquefaciens.
Authors: Paul D Cotter; Lucy H Deegan; Elaine M Lawton; Lorraine A Draper; Paula M O'Connor; Colin Hill; R Paul Ross Journal: Mol Microbiol Date: 2006-11 Impact factor: 3.501
Authors: Antony N Appleyard; Shaila Choi; Daniel M Read; Ann Lightfoot; Steven Boakes; Anja Hoffmann; Ian Chopra; Gabriele Bierbaum; Brian A M Rudd; Michael J Dawson; Jesus Cortes Journal: Chem Biol Date: 2009-05-29
Authors: Joana C Barbosa; Ítala C Silva; Tânia Caetano; Eva Mösker; Maria Seidel; Joana Lourenço; Roderich D Süssmuth; Nuno C Santos; Sónia Gonçalves; Sónia Mendo Journal: World J Microbiol Biotechnol Date: 2022-01-03 Impact factor: 3.312
Authors: Anton Du Preez van Staden; Tiaan Heunis; Carine Smith; Shelly Deane; Leon M T Dicks Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Kong Boon Lim; Marilen P Balolong; Sang Hoon Kim; Ju Kyoung Oh; Ji Yoon Lee; Dae-Kyung Kang Journal: Biomed Res Int Date: 2016-04-28 Impact factor: 3.411
Authors: Bishnu K Shrestha; Hari Sharan Karki; Donald E Groth; Nootjarin Jungkhun; Jong Hyun Ham Journal: PLoS One Date: 2016-01-14 Impact factor: 3.240